by The US mRNA therapeutics market size is poised to grow by USD 38.21 billion by 2033 from USD 11.07 billion in 2023, exhibiting a CAGR of 13.21% during the forecast period 2024-2033.
Key Points
- By type, the prophylactic vaccines segment held the largest share of the market in 2023.
- By application, the infectious disease segment led the market in 2023. The segment is observed to sustain the growth rate during the forecast period.
- By end-use, the hospital and clinics segment held the largest share of the market in 2023. The segment is expected to sustain its position throughout the forecast period.
Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the US mRNA therapeutics market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.
To begin with, the US mRNA therapeutics Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.
Get a Sample Report: https://www.precedenceresearch.com/sample/3862
US mRNA Therapeutics Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 13.21% |
| U.S. Market Size in 2023 | USD 11.07 Billion |
| U.S. Market Size by 2033 | USD 38.21 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type, By Application, and By End User |
Read More: Telecom Electronic Manufacturing Services Market Size, Growth Report By 2033
The empirical study on the global US mRNA therapeutics market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the US mRNA therapeutics Market. Our market report for the US mRNA therapeutics market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.
US mRNA Therapeutics Market Companies
- GSK plc.
- BioNTech SE
- CureVac N.V.
- Sangamo Therapeutics, Inc.
- Translate Bio, Inc.
- Moderna, Inc.
- Argos Therapeutics Inc.
- Arcturus Therapeutics
- AstraZeneca plc.
- Pfizer Inc.
- CRISPR Therapeutics AG
Data Sources and Methodology
To gather comprehensive insights on the Global US mRNA therapeutics Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.
We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global US mRNA therapeutics Market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the US mRNA therapeutics market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2024 to 2033.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Market Segmentation:
By Type
- Therapeutic Vaccines
- Prophylactic Vaccines
- Therapeutic Drugs
By Application
- Respiratory Diseases
- Oncology
- Rare Genetic Diseases
- Infectious Diseases
- Others
By End-use
- Research Organizations
- Hospitals & Clinics
- Others
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global US mRNA therapeutics market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global US mRNA therapeutics market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global US mRNA therapeutics market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global US mRNA therapeutics market but also the strategic plans of industry leaders.
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on US mRNA Therapeutics Market
5.1. COVID-19 Landscape: US mRNA Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global US mRNA Therapeutics Market, By Type
8.1. US mRNA Therapeutics Market, by Type, 2023-2032
8.1.1 Therapeutic Vaccines
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Prophylactic Vaccines
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Therapeutic Drugs
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global US mRNA Therapeutics Market, By Application
9.1. US mRNA Therapeutics Market, by Application, 2023-2032
9.1.1. Respiratory Diseases
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Rare Genetic Diseases
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Infectious Diseases
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global US mRNA Therapeutics Market, By End-use
10.1. US mRNA Therapeutics Market, by End-use, 2023-2032
10.1.1. Research Organizations
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Hospitals & Clinics
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global US mRNA Therapeutics Market, Trend Forecast
11.1. US
11.1.1. Market Revenue and Forecast, by Type (2020-2032)
11.1.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Forecast, by End-use (2020-2032)
US mRNA Therapeutics Market
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on US mRNA Therapeutics Market
5.1. COVID-19 Landscape: US mRNA Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global US mRNA Therapeutics Market, By Type
8.1. US mRNA Therapeutics Market, by Type, 2024-2033
8.1.1 Therapeutic Vaccines
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Prophylactic Vaccines
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Therapeutic Drugs
8.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global US mRNA Therapeutics Market, By Application
9.1. US mRNA Therapeutics Market, by Application, 2024-2033
9.1.1. Respiratory Diseases
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Rare Genetic Diseases
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Infectious Diseases
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global US mRNA Therapeutics Market, By End-use
10.1. US mRNA Therapeutics Market, by End-use, 2024-2033
10.1.1. Research Organizations
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Hospitals & Clinics
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global US mRNA Therapeutics Market, Trend Forecast
11.1. US
11.1.1. Market Revenue and Forecast, by Type (2021-2033)
11.1.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 12. Company Profiles
12.1. GSK plc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. BioNTech SE
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. CureVac N.V.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Sangamo Therapeutics, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Translate Bio, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Moderna, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Argos Therapeutics Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Arcturus Therapeutics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AstraZeneca plc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pfizer Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Unlocking Market Insights through Data Excellence
The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
Precedence Statistics – Empowering Your Data Insights
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
